At a glance
ClinicalIndex Comparison RecordPhase 2Not Yet Recruiting· 40 target
Drug / intervention
Blinatumomabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia
In Brief
A Phase 2 clinical trial evaluating Blinatumomab for Phase 2 Study and 2 related conditions. Not yet recruiting, targeting 40 participants across 1 site.
Detailed Summary
To find out if giving blinatumomab as injections under the skin can help to control MRD and keep the disease from coming back in participants with B-cell ALL.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPhase 2 Study, Blinatumomab, Acute Lymphoblastic Leukemia
CountriesUnited States
CollaboratorsAmgen
Timeline
Phase 2Not Yet Recruiting
2026202720282029203020312032
First PostedSep 2025
TodayJul 2026
Enrollment StartSep 2026
Primary CompletionOct 2030
Study CompletionOct 2032
First PostedSep 25, 2025
Enrollment StartSep 27, 2026
Primary CompletionOct 12, 2030
Study CompletionOct 12, 2032
TodayJul 1, 2026
Enrollment to primary: 4.0 yearsPosted 9 months agoPrimary completion in 4.3 years
Interventions
Blinatumomabdrug
Given by IV